322 related articles for article (PubMed ID: 24685974)
1. Combination phentermine/topiramate for obesity treatment in primary care: a review.
Xiong GL; Gadde KM
Postgrad Med; 2014 Mar; 126(2):110-6. PubMed ID: 24685974
[TBL] [Abstract][Full Text] [Related]
2. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
4. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
5. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
6. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
[TBL] [Abstract][Full Text] [Related]
7. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
8. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
9. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
10. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
11. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
12. Phentermine and topiramate extended-release for the obesity: new kids on the block.
Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
[TBL] [Abstract][Full Text] [Related]
13. Phentermine plus topiramate in the treatment of obesity.
Malgarini RB; Pimpinella G
Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167
[No Abstract] [Full Text] [Related]
14. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness Analysis of Qsymia for Weight Loss.
Finkelstein EA; Kruger E; Karnawat S
Pharmacoeconomics; 2015 Jul; 33(7):699-706. PubMed ID: 24986038
[TBL] [Abstract][Full Text] [Related]
16. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
17. 2 new drugs for weight loss.
Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
[No Abstract] [Full Text] [Related]
18. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
19. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
[TBL] [Abstract][Full Text] [Related]
20. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]